Teva Pharmaceuticals to make 1,000 of its employees redundant following its acquisition of US-based Cephalon last month.

The cuts represent approximately 27% of Cephalon’s entire workforce.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The company has expected to gather at least $500m in synergies as a result of the acquisition.

The layoffs will not affect Teva’s operations in its home nation Israel, but instead in the US and Europe.

Teva CEO Shlomo Yanai is currently in the US overseeing the merger of Cephalon’s interests.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Pharmaceutical Technology Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now